DNA Damage Response and Cancer Metastasis: Clinical Implications and Therapeutic Opportunities

Yin, Ming; Hong, Feng; Wang, Qi-En

doi:10.36255/exon-publications.metastasis.dna-damage-response

Cited by 2 publications

(2 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, epigenetic alterations of molecular pathways resulting from progression or treatment of primary cancers could potentially pave the ways for other simultaneous malignancies to emerge. For example, DNA damage repair (DDR) alterations, resulting from DDR gene mutations or epigenetic modifications, have been involved in cancer initiation, progression, and treatment response [15]. It has been revealed that DDR genes alterations including BRCA2, BRCA1, CDK12, ATM, FANCD2, or RAD51C affect almost 20% of 333 primary prostate cancer [16].…”

Section: Discussionmentioning

confidence: 99%

Prostate cancer, chronic myelogenous leukemia and multiple myeloma in a single patient: a case report and review of the literature

et al. 2023

View full text Add to dashboard Cite

Background Synchronous or metachronous multiple primary malignancies (MPMs) are a known phenomenon. These occurrences may be spontaneous or related to environmental risk factors or genetic predisposition. Chronic myelogenous leukemia (CML) and Multiple myeloma (MM) are two uncommon hematologic malignancies, arises from two different cell lineage. The coexistence of CML and MM that is a rare phenomenon, with only 29 cases reported in the literature. To the best of our, this combination of triple primary cancers has not been reported in a single patient. Case presentation Herein, we reported a case of an 85-year-old Iranian male with three confirmed primary malignant neoplasms. The patient presented with synchronous prostate cancer and CML, in august 2016. He received imatinib and nilotinib for CML and hormonal therapy for prostate cancer. He remained in good control at further follow-ups for about 5 years. In the follow-up period and after 61 months treatment with tyrosine kinase inhibitors (TKIs), CML was undetectable in molecular tests, but the presence of serum M-protein, abnormal plasma cells in the bone marrow, and CRAB criteria was compatible with MM. Conclusion We must evaluate the possibility of multiple primary cancers during cancer treatment and follow-up and it may be worthwhile to monitor serum electrophoresis and protein levels in TKIs-treated patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Prostate cancer, chronic myelogenous leukemia and multiple myeloma in a single patient: a case report and review of the literature

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Maintaining the integrity of the genome is crucial for any organism's survival [1]. Double-strand breaks (DSBs) are deemed as one of the most harmful forms of DNA damage since, if left unrepaired, they can result in cell death, or chromosomal rearrangements if inappropriately repaired, leading to cancer [2].…”

Section: Introductionmentioning

confidence: 99%

Uncovering the Molecular Drivers of NHEJ DNA Repair-Implicated Missense Variants and Their Functional Consequences

Al-Jarf,

Karmakar,

Myung

et al. 2023

Genes

View full text Add to dashboard Cite

Variants in non-homologous end joining (NHEJ) DNA repair genes are associated with various human syndromes, including microcephaly, growth delay, Fanconi anemia, and different hereditary cancers. However, very little has been done previously to systematically record the underlying molecular consequences of NHEJ variants and their link to phenotypic outcomes. In this study, a list of over 2983 missense variants of the principal components of the NHEJ system, including DNA Ligase IV, DNA-PKcs, Ku70/80 and XRCC4, reported in the clinical literature, was initially collected. The molecular consequences of variants were evaluated using in silico biophysical tools to quantitatively assess their impact on protein folding, dynamics, stability, and interactions. Cancer-causing and population variants within these NHEJ factors were statistically analyzed to identify molecular drivers. A comprehensive catalog of NHEJ variants from genes known to be mutated in cancer was curated, providing a resource for better understanding their role and molecular mechanisms in diseases. The variant analysis highlighted different molecular drivers among the distinct proteins, where cancer-driving variants in anchor proteins, such as Ku70/80, were more likely to affect key protein–protein interactions, whilst those in the enzymatic components, such as DNA-PKcs, were likely to be found in intolerant regions undergoing purifying selection. We believe that the information acquired in our database will be a powerful resource to better understand the role of non-homologous end-joining DNA repair in genetic disorders, and will serve as a source to inspire other investigations to understand the disease further, vital for the development of improved therapeutic strategies.

show abstract

DNA Damage Response and Cancer Metastasis: Clinical Implications and Therapeutic Opportunities

Cited by 2 publications

References 94 publications

Prostate cancer, chronic myelogenous leukemia and multiple myeloma in a single patient: a case report and review of the literature

Prostate cancer, chronic myelogenous leukemia and multiple myeloma in a single patient: a case report and review of the literature

Uncovering the Molecular Drivers of NHEJ DNA Repair-Implicated Missense Variants and Their Functional Consequences

Contact Info

Product

Resources

About